Larotrectinib Sulfate Suppliers & Bulk Manufacturers
Available Forms: Capsule / Oral suspension
Available Strengths: 25 mg, 100 mg, 20 mg/mL
Reference Brands: Vitrakvi (USA/EU/LATAM)
Category:
Oncology Cancer Care
Larotrectinib sulfate is available in Capsule / Oral suspension
and strengths such as 25 mg, 100 mg, 20 mg/mL.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Larotrectinib sulfate is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Larotrectinib sulfate can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Larotrectinib is a first-in-class, highly selective tropomyosin receptor kinase (TRK) inhibitor developed for the treatment of cancers driven by NTRK gene fusions. These gene fusions lead to the production of abnormal TRK proteins that promote uncontrolled cell growth and tumor development. By specifically targeting and inhibiting TRK proteins, larotrectinib helps block the signaling pathways responsible for cancer progression. This targeted mechanism allows the drug to act across different types of solid tumors, regardless of where the cancer started in the body, as long as the tumor carries an NTRK gene fusion.
Clinical studies have demonstrated the effectiveness of larotrectinib in both adult and pediatric patients with a wide range of solid tumors. The therapy has shown meaningful and durable responses, particularly in patients whose cancers are difficult to treat with conventional therapies. In expanded clinical evaluations involving adult patients with TRK fusion sarcomas, larotrectinib has shown promising efficacy while maintaining a manageable safety profile.
Because of its precision-targeted approach, larotrectinib represents an important advancement in modern oncology, supporting the growing role of biomarker-driven treatments in improving outcomes for patients with rare genetic alterations in cancer.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing